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ds.2012.0Abstract Basal cell carcinoma (BCC) is a non-melanoma skin cancer and is one of the commonest
malignancies of the skin encountered in daily clinical practice. It derives from non-keratinizing cells
that originate in the basal layer of the epidermis. It accounts for approximately 75% of all skin can-
cer in the world, and 53.2% in Iraqi patients. Generally, most BCC cases are sporadic, but it may
also appear in genetic disorders such as Gorlin’s syndrome, Rombo’s syndrome, and xeroderma
pigmentosa (XP). If left untreated, BCC will continue to invade locally and may result in substantial
tissue damage that compromises function and cosmetic look. Metastasis is an extremely rare event.
The tumor characteristically develops on sun-exposed skin of lighter-skinned individuals.
There are two main modalities of therapy including topical like: Imiquimod, 5-ﬂuorouracil (5-
FU), photodynamic therapy (PDT), radiation therapy (RT), topical & intralesional zinc sulfate
and topical 25% podophylline. While surgical one consists of: Moh’s Micrographic excision, stan-
dard excision, Curettage and desiccation (C&D), and cryosurgery.
After extensive reviewing of all modalities of therapy, in addition to our experience, we can con-
clude that all therapies could be effective in treatment of BCC. As each patient is unique so indi-
vidualized treatment plan should be tailored to each one.
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Basal cell carcinoma (BCC) is the most common malignant
tumor in humans that derives from non-keratinizing cells that
originate in the basal layer of the epidermis. It accounts for
approximately 75% of all skin cancer in the world, and 53.2%
in Iraqi patients (Akinci et al., 2008; Al-Waiz, 1998). Generally,
most BCC cases are sporadic, but it may also appear in genetic
disorders such asGorlin’s syndrome and xerodermapigmentosa
(Lacour, 2002). The majority of sporadic cases are induced by
sunlight, speciﬁcally UVB rays (Kim et al., 2002). The incidence
rate of this disease has been estimated to have increased between
20% and 80%worldwide over the last three decades (Mikilineni
and Weinstock, 2001). The overall increase in the number of
BCC over the last decades is attributed mostly to increased
UVR exposure due to both lifestyle changes and the depletedstratospheric ozone layer (Oikarinen and Raitio, 2000). If left
untreated, BCC will continue to invade locally and may result
in substantial tissue damage that compromises both function
and cosmetic appearance. Metastasis is an extremely rare event
(Crowson, 2006; Carucci and Leffell, 2008; Miller, 1991a,b).
BCC is more common in elderly individuals but is becoming
increasingly frequent in people younger than 50 years of age
(Crowson, 2006). The tumor characteristically develops on
sun-exposed skin of lighter-skinned individuals, with 20%
occurring on the nose.Men are affected slightly more often than
are women. The distribution of the lesions does not correlate
well with the area of maximum exposure to UVR in that BCCs
are common on the eyelids, at the inner canthus and behind the
ear, but uncommon on the back of the hand and forearm. The
palm, sole and vermilion of the lips are rarely involved (Crow-
son, 2006; Carucci and Leffell, 2008; Miller, 1991a,b). Risk fac-
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let light (UVL) exposure, light hair and eye color, northern
European ancestry, and inability to tan (Crowson, 2006). Pa-
tients with BCC are at increased risk for melanoma but not
for other internal malignancies. Bower et al. reported that indi-
viduals with BCC had a three folds increased risk for melanoma
but no increased risk for any other type of cancer (Crowson,
2006; Carucci and Leffell, 2008; Miller, 1991a,b).
The pathogenesis of BCC involves exposure to ultraviolet
light, particularly the ultraviolet B spectrum (290–320 nm) that
induces mutations in tumor suppressor genes (Crowson, 2006;
Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006;
Habif, 2004). Some studies indicate that intermittent brief holiday
exposures may place patients at higher risk than occupational
exposure (Carucci and Leffell, 2008; Miller, 1991a,b). Other fac-
tors that appear to be involved in the pathogenesis include muta-
tions in regulatory genes (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; Habif, 2004; MacKie and Quinn,
2004;McCormack et al., 1997; Kricker et al., 1995). The propen-
sity to develop multiple BCCs may be inherited and included
among heritable conditions predisposing to the development of
this epithelial cancer are nevoid basal cell carcinoma syndrome
or basal cell nevus syndrome (BCNS) (Gorlin’s syndrome), Ba-
zex’s syndrome, and Rombo’s syndrome (Crowson, 2006; Caru-
cci and Leffell, 2008;Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004; McCormack et al., 1997; Bale
et al., 1994). The role of the immune system in the pathogenesis
of skin cancer is not completely understood. Immunosuppressed
patients with lymphoma or leukemia and patients who have re-
ceived an organ transplant (Crowson, 2006; Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006; Habif, 2004; MacKie
andQuinn, 2004; Sharquie et al., 2011; Sharquie et al., in press-a;
Sharquie et al., 2007) have a marked increase in the incidence of
squamous cell carcinoma but only a slight increase in the inci-
dence of BCC (Crowson, 2006; Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; Habif, 2004; MacKie and Quinn,
2004; McCormack et al., 1997; Kricker et al., 1995; Bale et al.,
1994; Niazi and Lamberty, 1993; Sharquie et al., 2011; Sharquie
et al., in press-a; Sharquie et al., 2007). While patients with auto-
immune diseases like pemphigus vulgaris have no tendency to de-
velop skinmalignancy(Sharquie et al., in press-b).Also, vitiligo as
autoimmune disease has protection against skin cancers although
lacking melanin and this is due to high P53 suppresser protein in
the epidermis of patientswith vitiligo.While on contrary, patients
with albinismwho are also lackingmelanin have a high risk to de-
velop skin cancers (Sharquie et al., 2011). Bastiaens et al., found
that transplant recipients developedmore BCCson the trunk and
arms than did non-immunosuppressed patients. Patients with hu-
man immunodeﬁciency virus infection develop BCCs at the same
rate as immune-competent individuals, based on similar risk fac-
tors. Immuno-suppressed long-term alcoholics tend to develop
inﬁltrative BCCs with increased frequency (Crowson, 2006;
Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006;
Habif, 2004;MacKie andQuinn, 2004;McCormack et al., 1997).
2. Clinical manifestations
The presence of any friable, non-healing lesion should raise the
suspicion of skin cancer. Frequently, BCC is diagnosed in pa-
tients who state that the lesion bled brieﬂy then healed com-
pletely, only to recur. BCC usually develops on sun-exposedareas of the head and neck but can occur anywhere on the body.
Features include translucency, ulceration, telangiectasia, and
the presence of a rolled border. Characteristics may vary for dif-
ferent clinical sub-types, which include nodular, superﬁcial,
morpheaform, and pigmented BCCs and Fibroepithelioma of
Pinkus (FEP) Carucci and Leffell, 2008; Miller, 1991a,b; Rich-
ard et al., 2006; Habif, 2004.
2.1. Basal cell carcinoma sub-types
2.1.1. Nodular basal cell carcinoma
Is the most common clinical sub-type of BCC. It occurs most
commonly on the sun-exposed areas of the head and neck and
appears as a translucent papule or nodule depending on dura-
tion. There are usually telangiectasias and often a rolled bor-
der (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Habif, 2004; MacKie and Quinn, 2004).
2.1.2. Pigmented basal cell carcinoma
Is a sub-type of nodular BCC that exhibits increased melaniza-
tion. It is commonly pigmented in Iraq. Pigmented BCC ap-
pears as a hyper pigmented, translucent papule, which may
also be eroded. The differential diagnosis includes nodular
melanoma (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Habif, 2004; MacKie and Quinn, 2004; McCor-
mack et al., 1997).
2.1.3. Superﬁcial basal cell carcinoma
Occurs most commonly on the trunk and appears as an ery-
thematous patch, often well demarcated that resembles ecze-
ma. An isolated patch of ‘‘eczema’’ that does not respond to
treatment should raise suspicion for superﬁcial BCC (Carucci
and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004; McCormack et al., 1997).2.1.4. Morpheaform (sclerosing) basal cell carcinoma
Is an aggressive growth variant of BCC with a distinct clinical
and histological appearance. Lesions of morpheaform BCC
may have an ivory-white appearance and may resemble a scar
or a small lesion of morphea. Thus, the appearance of scar tis-
sue in the absence of trauma or previous surgical procedure or
the appearance of atypical-appearing scar tissue at the site of a
previously treated skin lesion should alert the clinician to the
possibility of morpheaform BCC and the need for biopsy
(Crowson, 2006; Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Habif, 2004; MacKie and Quinn, 2004).
2.1.5. Fibroepithelioma of pinkus
Classically presents as a pink papule, usually on the lower
back. It may be difﬁcult to distinguish from an acrochordon
or skin tags (Crowson, 2006; Carucci and Leffell, 2008; Miller,
1991a).2.2. Biologic behavior
2.2.1. Local invasion
The greatest danger of BCC results from local invasion. In
general, BCC is a slow-growing tumor that invades locally
44 K.E. Sharquie, A.A. Noaimirather than metastasizes (Crowson, 2006; Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006). The doubling time
is estimated to be between 6 months and 1 year. If left un-
treated, the tumor will progress to invade subcutaneous tissue,
muscle, and even bone. Tumors along the nasofacial or retro-
auricular sulcus may be extensive.
The lesion, which encompassed an entire side of the face,
including the maxillary sinus, apparently doubled over a 10-
year period and grew rapidly in the 2 years before hospital
admission. This scenario occurs in the context of physical
or psychiatric disability that interferes with judgment or ac-
cess to health care. Lethal extension to the central nervous
system from aggressive scalp BCC has been reported (Caru-
cci and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006;
Habif, 2004; MacKie and Quinn, 2004; McCormack et al.,
1997).
2.3. Perineural invasion
Is uncommon in BCC and occurs most often in histological
aggressive or recurrent lesions. In one series, Niazi and Lam-
berty identiﬁed perineural invasion in less than 0.2% of cases
(Carucci and Leffell, 2008; Niazi and Lamberty, 1993).
2.4. Metastasis
Occurs only rarely, with rates varying from 0.0028% to 0.55%
(Padgett and Hendrix, 2001; Efudex (Fluorouracil) Topical
Solution and Cream (Product Pamphlet), 2000; Reymann,
1979). Involvement of lymph nodes and lungs is most com-
mon. Overall, squamous differentiation was present in 15%
of the primary or metastatic tumors from the 170 cases re-
viewed. Aggressive histological characteristics, including mor-
pheaform features, squamous metaplasia, and perineural
invasion, have been identiﬁed as risk factors for metastasis
(Crowson, 2006; Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Habif, 2004; MacKie and Quinn, 2004;
McCormack et al., 1997).2.5. Diagnosis
The diagnosis is accomplished by accurate interpretation of the
skin biopsy results (Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Habif, 2004; MacKie and Quinn, 2004).2.6. Histopathology
Varies somewhat with sub-type, but most BCCs share some
common histological characteristics. The malignant basal cells
have large nuclei and relatively little cytoplasm. Usually, mito-
tic ﬁgures are absent. Frequently, retraction of stroma from tu-
mor islands is present, creating peritumoral lacunae that are
helpful in histopathological diagnosis.
Nodular BCC accounts for half of all BCCs and is character-
ized by nodules of large basophilic cells and stroma retraction.
Pigmented BCC shows histological features similar to those
of nodular BCC but with the addition of melanin (Carucci and
Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004).Superﬁcial BCC characterized microscopically by buds of
malignant cells extending into the dermis from the basal layer
of the epidermis (Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Habif, 2004; MacKie and Quinn, 2004;
McCormack et al., 1997).
Morpheaform BCC consists of strands of tumor cells
embedded within a dense ﬁbrous stroma. Tumor cells are clo-
sely packed and, in some cases, only one cell thick. Strands of
tumor extend deeply into the dermis. This cancer is often larger
than the clinical appearance indicates. Recurrent BCC may
also demonstrate inﬁltrating bands and nests of cancer cells
embedded within the ﬁbrous stroma of scar (Crowson, 2006;
Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al.,
2006; Habif, 2004; MacKie and Quinn, 2004).
In Fibroepithelioma Pinkus long strands of interwoven
basiloma cells are embedded in ﬁbrous stroma. Histologi-
cally, FEP shows features of reticulated seborrheic keratoses
and superﬁcial BCC (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; Habif, 2004; MacKie and
Quinn, 2004).
3. Treatment
The aims of any therapy selected for the treatment of BCC are
to ensure complete removal and destruction of the primary
tumor to prevent local recurrence and the need for further
therapeutic intervention. The enormous differences in the nat-
ural history, biology of the different subtypes of BCC and the
large number of treatment modalities available for the removal
and destruction of skin tumors mean that it is difﬁcult to draw
up rigid guidelines for the management of this common cancer.
Successful management of BCC requires a clear understanding
of the clinic-pathological factors that affect prognosis and a
good theoretical and practical knowledge of the strengths
and limitations of many different treatments available for the
treatment of BCCs. From published series on treatment out-
comes, it is clear that successful treatment can be achieved
by any one of the large range of therapies, subjected to appro-
priate matching of the treatment to the tumor characteristics
(Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al.,
2006; Habif, 2004; MacKie and Quinn, 2004).
In most cases, treatment selection is usually based on a clin-
ical assessment which considers a number of factors that are
known to inﬂuence tumor prognosis. These factors include tu-
mor size, tumor location, clinical subtype and ability to deﬁne
tumor margin. In addition to the tumor characteristics, other
factors such as the patient’s age, adequacy and success of pre-
vious treatments and coexisting medical conditions that inﬂu-
ence tumor biology or treatment tolerability need to be
considered. For reasons that are still unclear, BCC recurring
following radiotherapy is particularly difﬁcult to eradicate by
conventional surgical excision and this needs to be taken into
account when selecting the most appropriate therapy (Carucci
and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Mac-
Kie and Quinn, 2004). Destructive therapies used appropri-
ately with careful tumor selection can offer an effective
alternative to surgical excision for small primary tumors at
non-critical sites. A number of studies have shown that
curettage and cautery of low-risk BCCs can give cure rates
of up to 97%. Similar high cure rates have also been reported
for cryotherapy for low-risk BCCs. Tumor size has an impor-
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that the recurrence rate following curettage and cautery or
cryotherapy increases signiﬁcantly with increasing size (Caru-
cci and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006;
Habif, 2004; MacKie and Quinn, 2004).
In addition to recurrence risk, it is also important to bear in
mind that the morbidity associated with cryotherapy also in-
creases with increasing size. Conventional surgical excision
with predetermined margins based on the clinical characteris-
tics of the tumor is regarded by many as the most appropriate
therapy for most nodular BCCs and provides a specimen for
histological examination and assessment of the lateral and
deep margins. Information from studies of Mohs’ surgical
(MMS) specimens has provided useful information about the
probability of achieving complete excision in tumors with
predetermined margins in different sized BCCs (Carucci and
Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004; Rowe et al., 1989; Lawrence,
1999). So treatment of BCC could be divided into topical or
surgical therapies.3.1. Topical therapy
Topical therapy could be divided into chemical and physical
therapies and in all varieties of topical therapies safe margin
2–4 mm should be included by these interventions:
3.1.1. Chemical therapy
By using drugs, chemicals to be applied topically or injected
intralesionally are like Imiquimod 5% cream, 5-ﬂuorouracil
5% cream, veniblastin, bleomycin, solasodine glycoalkaoilds,
zinc sulfate, 25% podophyllin (Carucci and Leffell, 2008; Mill-
er, 1991a,b; Richard et al., 2006; Habif, 2004; MacKie and
Quinn, 2004; Sharquie et al., 2005; Punjabi et al., 2007; Heller,
1996; Sharquie et al., 2012; Huber et al., 2004; Vidal et al.,
2004; Berman et al., 2003; Moore and Strober, 2008; Love
et al., Dec 2009; Padgett and Hendrix, 2001; Efudex (Fluoro-
uracil) Topical Solution and Cream (Product Pamphlet),
2000; Reymann, 1979; Kim et al., 2004).
3.1.2. Physical therapy
Using either, light therapy (PDT)or cooling lesions through cryo-
therapy or applying heat by using electrotherapy desiccation.
In all modalities of treatment biopsy is strongly recom-
mended before treatment because patients may need further
therapy if any one of these topical modes fails (Carucci and
Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004; Foley, 2005).
The general indications for topical therapies are: small size,
multiple lesions, advancing age, contraindication for surgery,
immunosuppressed patients with BCC like renal transplant,
superﬁcial lesions, cost beneﬁt, surgery phobia and cosmetic
squeals.3.1.3. Imiquimod (5% cream)
Is a Toll-like receptor 7 agonist and is believed to induce inter-
feron-a and other cytokines to boost T helper 1 type immunity.
Imiquimod 5% cream has been used successfully to treatsuperﬁcial basal cell carcinomas (BCCs). In two double-blind,
randomized, vehicle-controlled trials, clinical and histological
clearance rates for dosing ﬁve and seven times per week were
75% and 73%, respectively, for superﬁcial BCC. In another
study, 10 of 19 nodular BCCs approximately 53% cleared after
treatment with Imiquimod.
In general, adverse side effects are limited to local skin reac-
tions. Follow-up in case series has generally been shorter than
that in retrospective studies of recurrence rates after deﬁnitive
surgical management (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; Huber et al., 2004; Vidal et al.,
2004; Berman et al., 2003; Moore and Strober, 2008; Love
et al., Dec 2009; Padgett and Hendrix, 2001).
Although the exact mode of action in treating BCC is not
known, a few suggested mechanisms follow: lymphocytes, den-
drites cells, and macrophages may be recruited into the area of
Imiquimod application. These cells may be activated via toll-
like receptors 7 and 8 (both of which recognize Imiquimod
as a legend) to release cytokines, particularly tumor necrosis
factor-alpha, interferon-alpha, and interleukin 6. Antitumor
effects, such as apoptosis; may then proceed, thereby inducing
tumor regression. Induction of tumor suppressor function via
the Notch signaling pathway in superﬁcial BCCs has also been
suggested as a mechanism of Imiquimod (Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006; Huber et al., 2004;
Vidal et al., 2004; Berman et al., 2003; Moore and Strober,
2008; Love et al., Dec 2009; Padgett and Hendrix, 2001).
The current recommended dosing frequency for the treatment
of superﬁcial BCC is 5 times per week for 6 weeks, but the
frequency and duration should be tailored to the individual
patient’s response and ability to tolerate the medication. Many
application schedules have been used, ranging from 3 times per
week to twice daily 7 d/wk. The duration of treatment varies
from 6 to 16 weeks. Superﬁcial BCC cure rates of 70–100%
should be expected after a 6-week course of 5-times-per-week
application, as shown in studies. Topical Imiquimod has also
been used to treat small, nodular BCCs in low-risk locations,
but cure rates have been lower than those with superﬁcial
BCCs (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Huber et al., 2004; Vidal et al., 2004; Berman
et al., 2003; Moore and Strober, 2008; Love et al., Dec 2009;
Padgett and Hendrix, 2001).
Although successful use of Imiquimod in immunosup-
pressed populations (e.g., transplantation patients) without
systemic complications has been documented, it has not been
widely studied, nor have safety and efﬁcacy been established.
Imiquimod should be used cautiously in patients with autoim-
mune disease. Additionally, its high cost may prohibit its use in
some patients (Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Huber et al., 2004; Vidal et al., 2004;
Berman et al., 2003; Moore and Strober, 2008; Love et al.,
Dec 2009; Padgett and Hendrix, 2001).
3.1.4. 5-Fluorouracil (5-FU)
Topical 5-ﬂuorouracil is sometimes used to treat small, super-
ﬁcial BCCs. It is a ﬂuorinated pyrimidine that ‘‘blocks the
methylation reaction of deoxyuridylic acid to thymidylic acid.
In this manner ﬂuorouracil interferes with the synthesis of
deoxyribonucleic acid (DNA) and to a lesser extent inhibits
the formation of ribonucleic acid (RNA). Since DNA and
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ﬂuorouracil may be to create a thymine deﬁciency which pro-
vokes unbalanced growth and death of the cell. In properly se-
lected (e.g., thin) tumors, cure rates of approximately 80%
have been obtained. It is generally applied twice daily and
must be used for at least 6 weeks for the treatment of superﬁ-
cial BCC (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Moore and Strober, 2008; Love et al., Dec 2009;
Padgett and Hendrix, 2001; Efudex (Fluorouracil) Topical
Solution and Cream (Product Pamphlet), 2000; Reymann,
1979). Percutaneous absorption of 5-ﬂuorouracil is its major
limiting factor; it penetrates only 1 mm into the skin. New
vehicles that may enhance absorption of 5-ﬂuorouracil are
being investigated. One advantage of 5-ﬂuorouracil use is that
it can act on BCCs that are not large enough to be seen with
the unaided eye. Therefore, it may be used in patients with ba-
sal cell nevus syndrome or in individuals prone to develop
many BCCs to preemptively treat subclinical tumors. Patients
with BCCs that are treated with 5-ﬂuorouracil should be mon-
itored carefully because not all tumors completely respond.
Cosmetic results tend to range from good to excellent with
the use of 5-ﬂuorouracil. Although it is not inexpensive, it does
cost less than Imiquimod (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; MacKie and Quinn, 2004;
Moore and Strober, 2008; Love et al., Dec 2009; Padgett and
Hendrix, 2001; Efudex (Fluorouracil) Topical Solution and
Cream (Product Pamphlet), 2000; Reymann, 1979).
3.1.5. Interferon alfa-2b (intron A)
Protein productmanufacturedwith recombinantDNA technol-
ogy. Mechanism of antitumor activity not clearly understood;
however, direct antiproliferative effects against malignant cells
and modulation of host immune response may be important
(Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al.,
2006; MacKie and Quinn, 2004; Moore and Strober, 2008;
Padgett and Hendrix, 2001; Kim et al., 2004). Interferon alfa-
2b has shown some success in treating small (<1 cm), nodular,
and superﬁcial BCCs. It is administered intralesionally, 3 times
perweek for 3 weeks. The recommended dose is 1.5 million units
per injection (total of 13.5 million U). In appropriate BCC tu-
mors, cures rates of up to 80% have been obtained. Interferon
has not become amainstay in BCC treatment because of its cost,
the inconvenience of multiple visits, the discomfort of adminis-
tration, and its adverse effects. Flu like symptoms, which are
dose related, are common with the doses administered to treat
BCCs. Cardiovascular, myelodepressive, and neurologic ad-
verse effects are less common with this treatment than with oth-
ers. Because interferon is an immune stimulant, it should not be
used to treat BCC in transplant recipients or in individuals with
autoimmune diseases (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; MacKie and Quinn, 2004;
Moore and Strober, 2008; Padgett and Hendrix, 2001; Kim
et al., 2004).
Interferon alfa-2b has been used for nodular BCC in a ran-
domized, placebo-controlled multicenter studies (172 subjects).
Intralesional injections of 1.5 million U were administered
3 times/wk for 3 wk yielded 86% complete-response rate;
29% for placebo. Similar study did not show efﬁcacy for
morpheaform or aggressive BCCs (Carucci and Leffell, 2008;
Miller, 1991a,b; Richard et al., 2006; MacKie and Quinn,2004; Moore and Strober, 2008; Padgett and Hendrix, 2001;
Kim et al., 2004).
3.1.6. Photodynamic therapy (PDT)
Photodynamic therapy for BCCs has been used for more than
20 years (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Moore and Strober, 2008; Padgett and Hendrix,
2001; Foley, 2005). PDT is the process of using speciﬁc wave-
lengths of light to photoexcite porphyrins that have been ap-
plied to neoplastic and preneoplastic cells. This increased
energy is rapidly absorbed by adjacent tissue oxygen, causing
the formation of singlet oxygen radicals. These radicals rapidly
react with adjacent tissue and destroy it. Five aminolevulinic
acid (ALA-PDT) is the only US Food and Drug Administra-
tion approved photo reactive molecule for PDT in the United
States, and it is only approved for actinic keratoses. It is
photoactivated with blue light for 1000 s after 1 h of incuba-
tion (Carucci and Leffell, 2008; Miller, 1991a,b; Richard
et al., 2006; Moore and Strober, 2008; Padgett and Hendrix,
2001; Foley, 2005). Although its use is off label, PDT has been
used for treatment and prevention of BCCs, including patients
with immunosuppression and nevoid BCC syndrome. Shallow
tumors, such as superﬁcial BCCs, respond most consistently.
Surgical excision has been shown to be signiﬁcantly more effec-
tive than ALA-PDT in the treatment of nodular BCC. The
strongest support for PDT as a modality for BCCs comes with
data on thin lesions treated with methylaminolevulinate (used
outside the United States), but at least one long-term follow-
up trial has also shown surgical excision to be superior.
Marmur et al. reviewed photodynamic therapy for non-mela-
noma skin cancer and reported recurrence rates ranging from
0% to 31% for BCC. Various protocols have been followed to
achieve varying levels of success––increasing the incubation
time, increasing occlusion time, and using longer and/or
deeper-penetrating wavelengths of light (e.g., red light or
pulse-dye laser). Many patients continue to prefer PDT
because of its short healing time, excellent cosmetic and rela-
tive affordability (Carucci and Leffell, 2008; Miller, 1991a,b;
Richard et al., 2006; Moore and Strober, 2008; Padgett and
Hendrix, 2001; Foley, 2005).
3.2. Bleomycin-mediated electrochemotherpy of BCC
It is a new technique, electroporation, enhances the antitumor
effects of a variety of chemotherapeutic agents. When used in
combination with conventional chemotherapy, the procedure
is termed electro-chemotherapy.
Exposure of cancerous tissues to pulses of electricity during
electrochemotherapy appears to increase cell membrane per-
meability and thus intracellular access to cytotoxic drugs. Elec-
trical pulses were delivered to tumor nodules by means of
caliper electrodes after systemic doses of bleomycin were
administered. Vital signs were closely monitored during appli-
cation of the electrical pulses. Complete response was seen in
two lesions. Only minimal local or systemic side effects were
noted in response to the therapy (Carucci and Leffell, 2008;
Miller, 1991a,b; Richard et al., 2006; Sharquie et al., in
press-b; Moore and Strober, 2008; Love et al., Dec 2009; Padg-
ett and Hendrix, 2001).
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Zinc is one of essential trace elements and zinc sulfate has been
used in many medical conditions especially skin diseases as a
topical or systemic oral drug; it is used topically in treatment
of severe herpes simplex infection, plane warts, melasma,
superﬁcial fungal infection and provides antioxidant photo
protection for the skin. Intralesional zinc sulfate is found to
be an effective therapy for cutaneous leishmaniasis, BCC,
xeroderma pigmentosa (XP) and in treatment of viral warts
(Sharquie et al., 2005; Punjabi et al., 2007; Heller, 1996; Shar-
quie and Al-Azzawi, 1996; Sharquie et al., 2007; Sharquie
et al., 2008).
Through an open-label case interventional work performed
in 2003, intralesional 2% zinc sulfate solution has been used in
the treatment of BCC (Sharquie et al., 2005).
Eleven patients (10 males and one female) with BCC were
included in this study; they had 100 lesion/s ranging from 1
to 46 per patient (one of the patients had Gorlin’s syndrome)
(13.72 ± 9.18) median of 2. Their ages ranged from 46 to 70
(61.18 ± 9.60) years, while the duration of the disease was be-
tween 7 months and 36 years (11 ± 11.35 ± 8.49) (median: 2).
A total of 100 lesions of BCC, (48 [48%] nodular, 45 [45%]
superﬁcial pigmented, 6 [6%] noduloulcerative and 1 [1%] cys-
tic) were inﬁltrated with zinc sulfate solution mixed up with
2% xylocain. The sites of lesions were 43 (43%) on the scalp,
34 (34%) face, 21 (21%) cheek and 2 (2%) on the chest. The
number of injections for each lesion ranged from 1 to 4
(2.06 ± 0.9661) injections. All lesions showed clinical cure:
18 (18%) lesions after ﬁrst injection, 52 (52%) lesions after
second injection, 29 (29%) lesion after third injection, and
one (1%) lesion after fourth injection. Local redness, swelling,
and tenderness were observed in all lesions. After 2–3 days lo-
cal necrosis with black eschar appeared in all treated lesions
that stayed for 10–14 days and then fell down leaving atrophic
scar. This scar gradually disappeared over time leaving a good
cosmetic appearance at the end of 8 months follow up. No pa-
tient complained of any systemic side effects. Follow up for
8 months showed no residual malignant cells which proved
by histopathological examination. The mechanism of action
cannot be speculated, although it has been reported that zinc
sulfate has local cytotoxic effects. Similarly, zinc sulfate cause
local necrosis in the treatment of verruca vulgaris and cutane-
ous leishmaniasis through intralesional injection. So the mode
of action of local injection is mainly through necrosis of lesion-
al tissue. In comparison with other modes of injections like ble-
omycin and interferon alfa-2b, these drugs are associated with
systemic side effects like ﬂu like illness as with interferon alfa-
2b also they take long duration to achieve healing of lesion in
comparison with intralesional 2% zinc sulfate solution.
In further work, topical 15–35% zinc sulfate solution was
used twice daily in treatment of hundreds of BCC lesions
and showed very high successful rate. Also, topical 15–35%
zinc sulfate solution was applied on lesions in patients with
XP and gave very encouraging therapeutic and prophylactic
results (Sharquie et al., 2007; Sharquie et al., 2008; Sharquie
et al., in press-c; Sharquie et al., 2009; World Health Organiza-
tion, 2001; Al-Hamdi et al., 2007; Sharquie et al., 2006;
Sharquie et al., 2008).
Zinc sulfate solution whether through topical or intrale-
sional way is indicated for treatment of multiple lesions, in pa-
tients that are genetically prone to malignancies like XP,epidermodysplasia verruciformis (EDV) and syndromes that
are liable for BCC to malignancies or in patients with surgery
phobia (Sharquie et al., 2007; Sharquie et al., 2008; Sharquie
et al., in press-c; Sharquie et al., 2009; World Health Organiza-
tion, 2001; Al-Hamdi et al., 2007; Sharquie et al., 2006; Shar-
quie et al., 2008).
Most recently zinc sulfate solution 25% was reported as an
effective topical therapy in the treatment of actinic keratosis
(Sharquie et al., 2012).
3.2.2. Podophyllin 25%
A recent single blind study (Sharquie et al., 2012), using topical
25% podophyllin resin in compound tincture of benzoin
showed 96% success rate in treatment of BCC and the details
of this study is as follow: Lesions were treated with 25% top-
ical podophyllin solution once weekly for 6 weeks. Follow up
after clinical cure was done every 3 months up to 18 months
to recording any sign and symptom of recurrence.
Thirty-ﬁve patients with basal cell carcinoma completed the
study: 28 (80%) males and 7 (20%) females with males to fe-
males ratio 4:1, their ages ranged from 30 to 87 (64.114 ±
12.68) years, and the duration of the disease ranged from
2 months to 30 years (6.88 ± 4.83). The size of lesions ranged
from 0.8 to 1.9 (1.454 ± 0.239) cm. The total podophyllin appli-
cations number ranged from 2 to 6 (4.65 ± 1.055) sessions. The
total numbers of treated lesions were 100 lesions: 64 (64%) nod-
ular, 31 (31%) pigmented, 3 (3%) basosquamous, and 2 (2%)
superﬁcial.
Ninety-six (96%) lesions in 32 patients showed complete
cure with 2–6 sessions while 4 lesions in 3 patients showed
partial response with 6 sessions Biopsy from 21 cured lesions
in 21 patients showed complete clearness apart from one with
residual malignant cells. All the patients did not show clinical
recurrence, during the follow up period up to 18 months.
Inﬂammatory reactions were noted in all treated lesions as
redness, edema and juicy skin 36–72 h after topical podophyl-
lin applications. After 3–5 days the reaction became more
exaggerated and ulceration developed, ended with crust
formation.
No evidence of systemic side effects was seen and this had
been conﬁrmed clinically and by laboratory tests during the
sessions and 1 months later. Minimal or no scarring was
noticed.
Topical 25% podophyllin solution is a new therapeutic
modality in treatment of basal cell carcinoma which gave
96% cure, and it is highly recommended as alternative therapy
in all type of basal cell carcinoma, single and multiple and for
all ages especially for elderly patients and those who have sur-
gery phobia.
No important side effects were noticed apart from erythema
and irritations will be considered a sign of positive reaction to
the drug (Sharquie et al., 2012).
3.2.3. Radiation therapy (RT)
Is effective as primary treatment for a variety of BCCs. For
most BCCs, cure rates approach 90%. It is especially useful
for patients who cannot easily tolerate surgery, such as elderly
or debilitated individuals. Irradiation can also be a useful ad-
junct when patients have aggressive tumors that were treated
surgically or when surgery has failed to clear the margins of
the tumor. Radiation is also an excellent option in patients
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imity to vital structures (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006).
Initial cosmetic results tend to be good, and this therapy
can be less disﬁguring than surgical excision. However, long-
term results after several years can be deforming. Another dis-
advantage of this technique is that surgical margins cannot be
examined. Tumors recurring in previously radiated sites tend
to be aggressive and extensive and difﬁcult to treat and recon-
struct. Radiation therapy remains an important, feasible op-
tion in selected patients with BCC (Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006; MacKie and
Quinn, 2004).
3.2.4. Cryosurgery
Is another destructive modality that has been used in the treat-
ment of BCC. Two freeze–thaw cycles with a tissue tempera-
ture of 50 C (58 F) are required to destroy BCC. In
addition, a margin of clinically normal tissue must be de-
stroyed to eradicate sub-clinical extension. Cryosurgery lacks
the beneﬁt of histological conﬁrmation of tumor removal.
Kuﬂik and Gage reported 99% cure rates in 628 patients
followed for 5 years. Possible complications of cryosurgery
include hypertrophic scarring and post-inﬂammatory pigmen-
tary changes. Another serious potential adverse outcome is the
obscuring of tumor recurrence by ﬁbrous scar tissue. Any re-
cent change in a cryosurgery scar after normal healing is com-
pleted should raise the suspicion of recurrent BCC (Carucci
and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Mac-
Kie and Quinn, 2004).
3.2.5. Heat therapy
By applying the heated electrocautery probe above lesions but
no touch and through the irradiated infrared light exposure
which causes heating of the tissues until boiling followed by
destruction of lesion. This mode of therapy is strongly indi-
cated in small lesions of all types of BCC (Sharquie personal
communication, 1995).3.2.6. Curettage and desiccation (C&D)
Is one of the most frequently used treatment modalities for
BCC. The C&D is operator dependent as was shown by Kopf
et al., who identiﬁed a signiﬁcant difference in cure rate be-
tween patients treated by private practitioners (94.3%) and
those treated by residents (81.2%). Spiller and Spiller reported
a cure rate of 97% in 233 patients. Cure rate decreased with
the increasing size lesion: for lesions smaller than 1.0 cm, the
cure rate was 98.8%; for lesions between 1.0 and 2.0 cm,
95.5%; and for lesions larger than 2.0 cm, 84%. Recurrences
were noted most often on the forehead, temple, ears, nose,
and shoulders. C&D is not recommended for large primary
BCC, morpheaform BCC, or recurrent BCC (Carucci and Lef-
fell, 2008; Miller, 1991a,b; Richard et al., 2006; MacKie and
Quinn, 2004).3.2.7. Modiﬁed C & D
After full curettage and desiccation, we do boiling the base and
the margin of curetted and desiccated BCC through heating
the electrocautery probe to become red in color and thenpassed over the treated area without touching the lesion until
we notice boiling of the lesion (Sharquie personal communica-
tion, 1995).
By using this maneuver we raise the cure rate to almost
100% with very low recurrence rate by destroying any residual
malignant cells.
3.2.8. Standard excision
Compared with non-excisional techniques, standard surgical
excision offers the advantage of histological evaluation of the
removed specimen. Although standard excision is appropriate
for many BCCs, cure rates for standard excisional surgery are
inferior to those for Mohs Micrographic Surgery (MMS) in
cases of primary morpheaform BCCs, recurrent BCCs, and
tumors located in high-risk anatomic sites (Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006; MacKie and
Quinn, 2004; Rowe et al., 1989; Lawrence, 1999). Wolf and
Zitelli demonstrated that margins of 4 mm were adequate for
95% of non-morpheaform BCCs smaller than 2 cm in
diameter when treated by standard excision (Carucci and Lef-
fell, 2008; Miller, 1991a,b; Richard et al., 2006; MacKie and
Quinn, 2004; Rowe et al., 1989; Lawrence, 1999). Johnson,
Tromovitch, and Swanson reported a 96.7% cure rate when
the excision included a 2-mm margin beyond the area deﬁned
by curettage. Tumor was present in 64 of 403 curette margins
and in 12 of 403 excision margins. The histological sub-type
was aggressive in 11 of 12 cases with positive excision margins.
Margins of 5 mm are necessary for primary morpheaform
BCC or recurrent BCC. Excision of primary BCC should ex-
tend to fat to ensure adequate tumor removal (Carucci and
Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Habif,
2004; MacKie and Quinn, 2004).
3.3. Special management issues
3.3.1. Mohs micrographic surgery (MMS)
Offers superior histologic analysis of tumor margins while per-
mitting maximal conservation of tissue compared with stan-
dard excisional surgery. Rowe, Carroll, and Day report a
recurrence rate of 1% for primary BCCs treated by MMS.
This was superior to the rate for other modalities, including
standard excision (10%), curettage and desiccation (C&D)
(7.7%), Radiotherapy (RT) (8.7%) and cryotherapy (7.5%).
Recurrent BCCs treated by MMS reappeared at a rate of
5.6%, which was again superior to the rate for other modali-
ties, including excision (17.6%), RT (9.8%), and C&D
(40%). MMS is the treatment of choice for morpheaform,
poorly delineated, incompletely removed, and otherwise
high-risk primary BCCs (Carucci and Leffell, 2008; Miller,
1991a,b; MacKie and Quinn, 2004; Sharquie et al., 2011; Rowe
et al., 1989; Lawrence, 1999). It is the preferred treatment for
recurrent BCC and for any BCC that occurs at a site where tis-
sue conservation is desired. MMS is particularly useful in
treating BBCs at high-risk anatomic sites, including the embry-
onic fusion planes represented by the nasofacial junction and
retroauricular sulcus (Carucci and Leffell, 2008; Miller,
1991a,b; Richard et al., 2006; Habif, 2004; MacKie and Quinn,
2004; McCormack et al., 1997; Kricker et al., 1995; Bale et al.,
1994; Niazi and Lamberty, 1993; Sharquie et al., 2011; Rowe
et al., 1989; Lawrence, 1999).
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(Carucci and Leffell, 2008; Rowe et al., 1989; Lawrence, 1999)
1- Location on a high-risk anatomic site including mask
area of face, scalp, anatomic fusion planes, periorbital
area/eyelid.
2- Tumor > 2 cm.
3- Aggressive histologic sub-type.
4- Recurrent tumor.
5- Incompletely excised basal cell carcinoma.
6- Location on previously irradiated skin.
7- Immunosuppression of patient after solid organ
transplantation.
8- Indistinct clinical border.
9- Situation requiring conservation of normal tissue to pre-
serve function and cosmetics.
10- Situation requiring highest achievable probability of
cure to preserve function and cosmetics.
3.4.1. Incompletely excised basal cell carcinoma
The most widely cited article, and the one on which most
authors who advocate wait-and-see approach despite positive
tumor margins base their rationale, was published by Gooding
et al. (1965). A wait-and-see approach was taken in 66 patients
with positive margins and those patients were followed for at
least 5 years. The recurrence rate was 34.8% (a ﬁgure which
would decrease to 19% if patients who did not complete the
5 years of follow-up due to death or other reasons were not
excluded). Patients with clinical recurrence successfully under-
went surgery or radiotherapy. With these ﬁndings, the authors
concluded that, in view of the indolent nature of this tumor,
when faced with the presence of positive tumor margins in the
initial excision, it is preferable to wait and see and then treat
only in patients with clinical recurrence (Gooding et al., 1965).
A wait-and-see approach might be the most appropriate in
small primary basal cell carcinomas that have positive lateral
margins, occur at sites other than the ears or the center of
the face, and have a nodular or superﬁcial histology, and in el-
derly patients with multiple complaints or a short life expec-
tancy. In contrast, re-excision seems to be most appropriate
in high risk recurrent tumors that meet one or more of the fol-
lowing criteria: tumors located on the ears or center of the
face, greater than 2 cm in diameter, recurrent lesions, previ-
ously treated by radiotherapy, and tumors comprising
aggressive histological types including perineural, periadnexal,
or perivascular invasion and tumors with an inﬁltrative
appearance. Positive deep margins should also be considered
for aggressive treatment (Telfer et al., 1999; Sterry, 2006;
Dandurand et al., 2006).
Although no conclusive evidence is available, the studies
analyzed and common sense suggests that a wait-and-see ap-
proach in patients with aggressive tumors may be risky and
that a ﬂexible approach that combines monitoring, surgery,
and radiotherapy (or other treatments) may achieve good out-
comes in less aggressive tumors (Rı´os-Buceta, 2007).
3.4.2. Neurotropic basal cell carcinoma
Perineural invasion by BCC is a rare event (< 0.2% of cases)
Carucci and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006.When perineural invasion is detected; every effort should be
made to clear the tumor, preferably by MMS. Patients with
gross perineural invasion manifested by neurologic symptoms
would beneﬁt from preoperative magnetic resonance imaging
to assess extent of tumor spread. Classic examples include
brow paralysis due to involvement of the temporal branch of
the facial nerve and mid-face paresthesias secondary to
involvement of the trigeminal nerve (Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006).
3.4.3. Metastatic basal cell carcinoma
Although it is exceedingly rare, the possibility of metastatic
disease exists and may need to be addressed. If nodal disease
is suspected on surgical examination, lymph node biopsy and
imaging studies, as well as evaluation by medical and surgical
oncologists, are indicated. Platinum-based chemotherapy has
been used with modest results in treatment of metastatic
BCC; however, rapid clinical response was reported using a
combination of cisplatin and paclitaxel (Carucci and Leffell,
2008; Miller, 1991a,b; Richard et al., 2006; MacKie and
Quinn, 2004).
Most recently FDA approved drug called Erivedge (vis-
modegib) capsule for treatment of BCC. Erivedge is an oral
medicine designed to selectively inhibit abnormal signaling in
the Hedgehog pathway, which is an underlying molecular dri-
ver of BCC (Tang and Marghoob, 2011; Amin et al., 2010;
Von Hoff et al., 2009; Yauch et al., 2008; Fan et al., 2004;
Dierks et al., 2007; Low and de Sauvage, 2010; McMahon
et al., 2003; Chen et al., 2002).
The FDA approved vismodegib for the treatment of ad-
vanced BCC on January 30th 2012.The indication is for
BCC that has metastasized or relapsed after treatment with
surgery, or for those who are not candidates for surgery or
radiation. A boxed warning associated with this drug will
state that use of this drug can result in embryo-fetal death
or severe birth defects. Women need to be advised to use con-
traception and men need to be aware of the risk of vismode-
gib exposure through semen. In conclusion, vismodegib
represents the ﬁrst FDA-approved drug for use in advance
forms of the most common skin cancer. Further clinical re-
search will hopefully expand upon the indications for this
Shh inhibitor and future studies result in the addition of vis-
modegib to the treatment armamentarium for those with
operable BCC (Chen et al., 2002; Rudin et al., 2009; Tang,
2011; Roche Media Release, 2011; NIH Hedgehog Inhibitor
Clinical Trials Locator; FDA approves vismodegib for ada-
vanced basal cell carcinoma.).
3.4.4. Course and prognosis
With appropriate treatment, the prognosis for most patients
with BCC is excellent. Control rates as high as 99% have been
achieved by MMS. Although tumor control rates for primary
tumors are high, patients must be monitored for recurrence
and development of new primary BCCs. The risk for develop-
ment of a second primary BCC ranges from 36% to 50%. Peri-
odic full-body skin examinations and counseling about sun
protection are recommended for any patient with a history
of BCC. This is especially important because patients with a
history of BCC are at increased risk for melanoma (Carucci
and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Mac-
Kie and Quinn, 2004).
50 K.E. Sharquie, A.A. NoaimiThe prognosis for patients with recurrent BCC is favorable,
although recurrent tumors are more likely to appear again and
to behave aggressively. Patients with a history of recurrent dis-
ease must be monitored more frequently for the development
of further recurrences and new primary tumors. For the rare
patient with metastatic disease, prognosis is poor, with a mean
survival of 8–10 months from the time of diagnosis (Carucci
and Leffell, 2008; Miller, 1991a,b; Richard et al., 2006; Mac-
Kie and Quinn, 2004).
4. Conclusions
After extensive reviewing of all modalities of treatment in addi-
tion to our experience, we can conclude that all therapies
whether topical or surgical are effective mode of treatment
and there are no absolute contraindications for any of them
and each therapy should be tailored to each patient.
Moh’s surgery although it is good and precise type of ther-
apy but unfortunately it is carried out only in few centers in the
World and it takes long time and highly costly therapy, in
addition to its psychological trauma to the patients.
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